SCHEMBL2263756

SCHEMBL2263756

Cc1cc(O)cc(C)c1C[C@H](NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACE P12821 1/20 0.52
PPARA Q07869 6/20 0.47
ITGB3 P05106 2/20 0.46
ITGA2B P08514 2/20 0.46
CTSS P25774 4/20 0.46
CTSK P43235 2/20 0.46
PPARG P37231 5/20 0.46
PTPN1 P18031 3/20 0.45
ITGB1 P05556 1/20 0.44
ITGAV P06756 1/20 0.44
ITGB5 P18084 1/20 0.44
PPARD Q03181 2/20 0.43
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
SCN9A Q15858 1/20 0.42
IDO1 P14902 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1055585 1.00 ACE (0.52) ACEPPARAITGB3ITGA2BCTSS
SCHEMBL28483185 0.92 ACE (0.46) ACEPPARAITGB3ITGA2BCTSS
SCHEMBL10477452 0.91 ACE (0.47) ACEPPARAITGB3ITGA2BCTSS
SCHEMBL10477455 0.91 ACE (0.47) ACEPPARAITGB3ITGA2BCTSS
SCHEMBL10604860 0.90 ACE (0.53) ACEPPARAITGB3ITGA2BCTSS
SCHEMBL2890189 0.90 ACE (0.53) ACEPPARAITGB3ITGA2BCTSS
SCHEMBL22563312 0.90 KMT2A (0.45) ACEPPARAITGB3ITGA2BCTSS
SCHEMBL10477362 0.89 ACE (0.46) ACEPPARAITGB3ITGA2BCTSS
SCHEMBL10477361 0.89 ACE (0.46) ACEPPARAITGB3ITGA2BCTSS
SCHEMBL12294697 0.89 CTSS (0.44) ACEPPARACTSSCTSKPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117865851-A Fmoc-2, 6-dimethyl tyrosine synthesis method 上海吉奉生物科技有限公司 2024-04-12 CN disclosed
US-20240059734-A1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC. 2024-02-22 US disclosed
US-11795196-B2 Mitochondria-targeting peptides STEALTH BIOTHERAPEUTICS INC. (US) 2023-10-24 US disclosed
US-11795196-B2 Mitochondria-targeting peptides STEALTH BIOTHERAPEUTICS INC. (US) 2023-10-24 US disclosed
EP-4218785-A2 MITOCHONDRIA-TARGETING PEPTIDES Stealth BioTherapeutics Inc. (US) 2023-08-02 EP disclosed
EP-4218785-A2 MITOCHONDRIA-TARGETING PEPTIDES Stealth BioTherapeutics Inc. (US) 2023-08-02 EP disclosed
US-20230146515-A1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC. 2023-05-11 US disclosed
US-20230146515-A1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC. 2023-05-11 US disclosed
EP-3723783-B1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC (US) 2023-02-15 EP disclosed
EP-3723783-B1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC (US) 2023-02-15 EP disclosed
US-4722922-A RENIN INHIBITION G. D. SEARLE & CO. (US) 1988-02-02 US disclosed
EP-0215297-A2 Substituted dipeptide amides G.D. Searle & Co. (US) 1987-03-25 EP disclosed
EP-0213481-A2 N-terminally substituted dipeptide amides No. 2 G.D. Searle & Co. (US) 1987-03-11 EP disclosed
EP-0212550-A2 Substituted dipeptide amides G.D. Searle & Co. (US) 1987-03-04 EP disclosed
US-4603121-A ANALGESICS G. D. SEARLE & CO. (US) 1986-07-29 US disclosed
US-4599325-A ANALGESIC, HYPOTENSIVE G. D. SEARLE & CO. (US) 1986-07-08 US disclosed
EP-0154234-A2 Substituted tyrosil alanine dipeptide amides G.D. Searle & Co. (US) 1985-09-11 EP disclosed
EP-0136720-A2 Enkephalin analogs G.D. Searle & Co. (US) 1985-04-10 EP disclosed
US-4495178-A Enkephalin analogs G. D. SEARLE & CO. (US) 1985-01-22 US disclosed
US-4273704-A N-Adamantane-substituted tetrapeptide amides G. D. SEARLE & CO. (US) 1981-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795196-B2 Mitochondria-targeting peptides HSPE1, TFAM, TNNI3 ACE 4361/4885PPARA 1208/4885ITGB3 3517/4885
US-20240059734-A1 MITOCHONDRIA-TARGETING PEPTIDES HSPE1, TFAM, TNNI3 ACE 4361/4885PPARA 1208/4885ITGB3 3517/4885
US-20230146515-A1 MITOCHONDRIA-TARGETING PEPTIDES HSPE1, TFAM, TNNI3 ACE 4361/4885PPARA 1208/4885ITGB3 3517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.